



## **Novavax to Participate in the Citi 12th Annual Biotech Conference**

September 5, 2017

GAITHERSBURG, Md., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in Citi's 12<sup>th</sup> Annual Biotech Conference.

Conference details are as follows:

Date: Thursday, September 7, 2017

Location: Mandarin Oriental hotel, Boston, MA

### **About Novavax**

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, [novavax.com](http://novavax.com).

Contact:

Investor Relations

Novavax, Inc. Andrea N. Flynn, Ph.D.

Director, Investor Relations

[ir@novavax.com](mailto:ir@novavax.com)

240-268-2000

Westwicke Partners

John Woolford

[john.woolford@westwicke.com](mailto:john.woolford@westwicke.com)

443-213-0506

Media

Russo Partners, LLC

David Schull

Maggie Beller

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

[maggie.beller@russopartnersllc.com](mailto:maggie.beller@russopartnersllc.com)

212-845-4271



Novavax, Inc.